SCHEMBL1273137

SCHEMBL1273137

CCCCCCCC/C=C\CCCCCCC(O)C(=O)OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZDHHC7 Q9NXF8 1/20 0.53
GPR84 Q9NQS5 3/20 0.50
FFAR1 O14842 2/20 0.50
FFAR4 Q5NUL3 1/20 0.50
DGKA P23743 1/20 0.49
FAAH O00519 3/20 0.47
TERT O14746 3/20 0.47
MAPT P10636 2/20 0.47
BLM P54132 2/20 0.47
HSD17B10 Q99714 2/20 0.47
FABP4 P15090 2/20 0.47
PTPN1 P18031 2/20 0.47
PPARG P37231 2/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 2/20 0.47
GMNN O75496 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1683846 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL16007077 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL28810689 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL5809066 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL5809063 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL16007079 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL28233847 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL1273138 1.00 ZDHHC7 (0.53) ZDHHC7GPR84FFAR1FFAR4DGKA
SCHEMBL27786702 0.95 ALDH1A1 (0.51) FFAR1FFAR4HSD17B10FABP4PPARG
SCHEMBL25367237 0.89 ZDHHC7 (0.63) ZDHHC7GPR84FFAR1FFAR4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130211033-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS MEURICE R&D ASBL (BE) 2013-08-15 US claimed
US-20240374734-A1 Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate INTEGRATED NANOTHERAPEUTICS INC. (CA) 2024-11-14 US disclosed
CN-118215496-A Immunomodulatory combinations of antigens and drug-lipid conjugates 集成纳米治疗股份有限公司 2024-06-18 CN disclosed
EP-3941897-A1 LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY Integrated Nanotherapeutics Inc. (CA) 2022-01-26 EP disclosed
CN-113853368-A Lipid conjugates prepared from scaffold moieties 集成纳米治疗股份有限公司 2021-12-28 CN disclosed
US-20180134680-A1 METHOD FOR PRODUCING CYCLIC ESTERS BASF SE (DE) 2018-05-17 US disclosed
US-9018409-B2 Process for functionalization of unsaturated compounds MEURICE R&D ASBL (BE) 2015-04-28 US disclosed
US-20130211033-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS MEURICE R&D ASBL (BE) 2013-08-15 US disclosed
US-8173825-B2 Reacting unsaturated fatty acid or ester with an epoxidation reagent to form a fatty acid epoxide with an oxirane ring, then reacting with a carboxylic acid to form a hydroxy fatty acid ester derivative where the oxirane ring is opened to form a hydroxy ester; mild conditions, high yield, catalyst free THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2012-05-08 US disclosed
US-20110126325-A1 RECOMBINANT CELLS AND METHODS FOR HYDROXYLATING FATTY ACIDS COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION 2011-05-26 US disclosed
EP-2283137-A1 RECOMBINANT CELLS AND METHODS FOR HYDROXYLATING FATTY ACIDS Commonwealth Scientific and Industrial Research Organisation (AU) 2011-02-16 EP disclosed
WO-2009129583-A1 RECOMBINANT CELLS AND METHODS FOR HYDROXYLATING FATTY ACIDS COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION (AU) 2009-10-29 WO disclosed
US-20090186761-A1 Use of bio-derived surfactants for mitigating damage to plants from pests CLEARESO, LLC 2009-07-23 US disclosed
WO-2008079901-A2 METHOD OF MAKING FATTY ACID ESTER DERIVATIVES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2008-07-03 WO disclosed
US-20080154053-A1 Method of making fatty acid ester derivatives THE UNITES STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134680-A1 METHOD FOR PRODUCING CYCLIC ESTERS OR51E2, HSD17B12, OR10J3 ZDHHC7 561/4885GPR84 1371/4885FFAR1 361/4885
US-20130211033-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS F10, RPP30, PUF60 ZDHHC7 2124/4885GPR84 808/4885FFAR1 301/4885
US-20090186761-A1 Use of bio-derived surfactants for mitigating damage to plants from pests SGMS2, SGMS1, PHOSPHO1 ZDHHC7 435/4885GPR84 1232/4885FFAR1 760/4885
US-20240374734-A1 Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate LY96, CD74, TLR9 ZDHHC7 689/4885GPR84 1449/4885FFAR1 1614/4885
US-20080154053-A1 Method of making fatty acid ester derivatives FASN, ALOX5, ELOVL1 ZDHHC7 167/4885GPR84 671/4885FFAR1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.